Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Carmen, Santander"'
Publikováno v:
Current Oncology, Vol 28, Iss 4, Pp 2346-2350 (2021)
In current clinical guidelines, such as those provided by the National Comprehensive Cancer Network (NCCN), evidence for treatment is based on a small clinical trial that included patients with HLRCC. They support the use of the combination of erloti
Externí odkaz:
https://doaj.org/article/028ce97b3d3f45fa94e9f54ff968b4f1
Autor:
María P. Fernandez‐Perez, Enrique Perez‐Navarro, Teresa Alonso‐Gordoa, Vicenza Conteduca, Albert Font, Sergio Vázquez‐Estévez, Aránzazu González‐del‐Alba, Daniel Wetterskog, Emmanuel S. Antonarakis, Begona Mellado, Ovidio Fernandez‐Calvo, María J. Méndez‐Vidal, Miguel A. Climent, Ignacio Duran, Enrique Gallardo, Angel Rodriguez Sanchez, Carmen Santander, Maria I. Sáez, Javier Puente, Julian Tudela, Alberto Martínez, Maria J. López‐Andreo, José Padilla, Rebeca Lozano, David Hervas, Jun Luo, Ugo de Giorgi, Daniel Castellano, Gerhardt Attard, Enrique Grande, Enrique Gonzalez‐Billalabeitia
Publikováno v:
The Prostate. 83:376-384
Background There is a considerable need to incorporate biomarkers of resistance to new antiandrogen agents in the management of castration-resistant prostate cancer (CRPC). Methods We conducted a phase II trial of enzalutamide in first-line chemo-na
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73193786f45472a6e4883af37944503c
https://doi.org/10.1002/pros.24469
https://doi.org/10.1002/pros.24469
Autor:
Laura Villalobos-León, Iciar García, María Garrido Arévalo, Urbano Anido, Julia Llinares, O. Fernández, Arancha García, Alvaro Pinto, Xavier Garcia del Muro, J. Lambea, José Carlos Villa-Guzmán, Francisco Zambrana, Enrique Gallardo, M. Victoria Bolós, Alejandro Velastegui, Jesús García-Donas, José Muñoz-Langa, Antonio Viana, Esther Martínez-Ortega, María José Méndez-Vidal, Clara Iglesias, Susana Hernando-Polo, Daniel Castellano, Sara Cerezo, Carmen Santander, Martín Lázaro-Quintela, Miguel Angel Climent, Georgia Anguera, Laia Capdevila, Isabel Chirivella, Carolina Hernández, Alejo Rodriguez-Vida, Cristina Suárez, Sergio Vázquez, Aranzazu Gonzalez del Alba, Marc Campayo, Teresa Alonso, Miguel Sotelo, Ángel Rodríguez-Sánchez, Nuria Lainez, Gustavo Rubio, Òscar Reig, Rosa García-Marrero
Publikováno v:
CLINICAL GENITOURINARY CANCER
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Clinical Genitourinary Cancer
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Banco de España
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Clinical Genitourinary Cancer
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Banco de España
Background : Axitinib monotherapy obtained approval in pre-treated metastatic renal cell carcinoma (mRCC) patients and recently in combination with pembrolizumab or avelumab in the first-line setting. However, patient profiles that may obtain increas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ac76f384b4de54ba93be0a00b54c0d0
https://doi.org/10.1016/j.clgc.2021.09.006
https://doi.org/10.1016/j.clgc.2021.09.006
Autor:
Miguel A. Climent, Albert Font, Ignacio Durán, Javier Puente, María José Méndez-Vidal, María Isabel Sáez, Carmen Santander Lobera, Jóse Ángel Arranz Arija, Aranzazu González-del-Alba, Alfredo Sánchez-Hernandez, Maria Jose Juan Fita, Emilio Esteban, Teresa Alonso-Gordoa, Begoña Mellado Gonzalez, Pablo Maroto, Martín Lázaro-Quintela, Javier Cassinello-Espinosa, Begoña Pérez-Valderrama, Carmen Garcias, Daniel Castellano
We aimed to compare the efficacy and safety of maintaining or withdrawing abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-resistant prostate cancer who had experienced cancer progression to this treatment and were beg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::059cf185aa13df31a0c4383267bf4b5b
https://hdl.handle.net/10668/22179
https://hdl.handle.net/10668/22179
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Current Oncology, Vol 28, Iss 216, Pp 2346-2350 (2021)
Current Oncology
Current Oncology
In current clinical guidelines, such as those provided by the National Comprehensive Cancer Network (NCCN), evidence for treatment is based on a small clinical trial that included patients with HLRCC. They support the use of the combination of erloti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07cf5a5d4e2736b471ece94c9733f3d2
https://doi.org/10.3390/curroncol28040216
https://doi.org/10.3390/curroncol28040216
Autor:
Eva, Salas, Laura, Enguita, Raquel, Espílez, Carmen, Santander, Ángel, Borque-Fernando, María Jesús, Gil
Publikováno v:
Archivos espanoles de urologia. 75(3)
Lymphoepitheliomalikedifferentiation is a rare histological variant of urothelialbladder carcinoma, therefore its prognosis and treatmentare not clearly defined. A retrospective study of 5cases in the last 10 years in our center was performed.cystect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d27501031a56ba2a3919178995d6f02e
https://pubmed.ncbi.nlm.nih.gov/35435164
https://pubmed.ncbi.nlm.nih.gov/35435164
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Xavier Garcia del Muro, François Riva, M. Andres Cuellar, Pablo Maroto-Rey, Daniel E. Castellano, Patrizia Giannatempo, Miguel Angel A. Climent Duran, Andrea Necchi, Begoña Pérez-Valderrama, Alfonso Gomez De Liano Lista, Carmen Garcias-Espana, Javier Puente, Silverio Ros, Carmen Santander, Cristina Masini, Marta Martínez de Falcon, Almudena Garcia, Miguel Sampayo-Cordero, Andrea Malfettone, David Paez
Publikováno v:
Journal of Clinical Oncology. 40:TPS8-TPS8
TPS8 Background: PSqCC is a rare tumor with poor prognosis and limited therapeutic options. The current standard of care for advanced disease has been palliative platinum-based chemotherapy, with only marginal survival benefit. Recent data has shown
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::242ef980d16987652aedb89b50b78b55
https://doi.org/10.1200/jco.2022.40.6_suppl.tps8
https://doi.org/10.1200/jco.2022.40.6_suppl.tps8
Autor:
Miguel Angel A. Climent Duran, Jose Luis Perez-Gracia, Jose Angel Arranz Arija, Carlos Alvarez-Fernandez, Jenifer Gomez Mediavilla, Angel Rodriguez, Sergio Vazquez-Estevez, Jose Miguel Jurado, Carmen Santander, Teresa Bonfill, Carmen Molins Palau, Sara Perez Ramirez, Paola Pimentel Cáceres, Pablo Arnáiz, Zita Garate, Atenea Soto, Javier Puente
Publikováno v:
Journal of Clinical Oncology. 40:484-484
484 Background: Atezolizumab is a monoclonal antibody with proven efficacy in clinical trials for advanced or metastatic urothelial carcinoma (UC) after progression to platinum-based chemotherapy. Following EMA marketing authorization and before priz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b92b6d8cc15799ca2eeafa06306e7d84
https://doi.org/10.1200/jco.2022.40.6_suppl.484
https://doi.org/10.1200/jco.2022.40.6_suppl.484